Potassium chloride

Generic name: potassium chloride · Brand names: Brands MedlinePlus lists for potassium products (all forms; marketed and discontinued) include: K-Tab Filmtab, Klor-Con 10, K-Dur 10, Micro-K, Slow-K, Klotrix, K-Lor, Glu-K, K+ 10. The brand matching extended-release tablets was not matched to a label.

Quick facts

Drug class
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42, Description
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Potassium chloride is an electrolyte replenisher.
Rx or otc
Rx (label header: Rx Only; DailyMed Product Type: HUMAN PRESCRIPTION DRUG)
Forms and strengths
  • Potassium chloride extended-release tablets, USP 20 mEq: white to off-white, capsule-shaped biconvex tablets debossed with ‘472’ on one side and scored on the other side. 10 mEq: white to off-white, capsule-shaped biconvex tablets debossed with ‘471’ on one side and plain on the other side. (How Supplied)
  • 20 mEq tablet = 1500 mg microencapsulated potassium chloride; 10 mEq tablet = 750 mg (Description)
Generic available
Value
Yes. This is a generic (ANDA203562, Glenmark) label.
Source
DailyMed label Marketing Information: ANDA ANDA203562 https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Common use one line
Potassium supplement used to treat and prevent low blood potassium (hypokalemia).

What it is used for

Potassium chloride extended-release tablets treat low blood potassium (hypokalemia), including in digitalis intoxication and hypokalemic familial periodic paralysis, and help prevent low potassium in people at special risk, such as those taking digitalis or with serious heart rhythm problems. Because of reports of stomach and intestinal ulcers and bleeding with controlled-release products, they are reserved for people who cannot tolerate or refuse liquid or effervescent potassium, or who have trouble following those products.
Section
INDICATIONS AND USAGE
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

How it works

Potassium is the main positive ion inside body cells. It helps keep cells balanced, carry nerve signals, make heart, skeletal, and smooth muscles contract, and keep the kidneys working normally. The normal adult plasma concentration is 3.5 to 5 mEq per liter. Potassium chloride replaces potassium the body has lost.
Section
CLINICAL PHARMACOLOGY
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function. The normal adult plasma concentration is 3.5 to 5 mEq per liter. Potassium chloride is an electrolyte replenisher.

Dosage: adults

The dose is set for each person. To prevent low potassium, the usual dose is about 20 mEq a day. To treat potassium depletion, doses of 40 mEq to 100 mEq a day or more are used. If more than 20 mEq a day is needed, the dose is split so that no more than 20 mEq is taken at once. Take it with meals and a glass of water or other liquid, not on an empty stomach.
Section
DOSAGE AND ADMINISTRATION
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 mEq to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose. Each potassium chloride extended-release tablet, USP 20 mEq provides 20 mEq of potassium. Each potassium chloride extended-release tablet, USP 10 mEq provides 10 mEq of potassium. Potassium chloride tablets, USP should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS).

Dosage: children

Safety and effectiveness in children have not been established.
Section
PRECAUTIONS, Pediatric Use
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
Safety and effectiveness in pediatric patients have not been established.

Dosage adjustments

Drug interaction caps
The label gives no dose caps for interactions. It says to monitor potassium closely with RAAS drugs and NSAIDs and not to treat low potassium with a potassium-sparing diuretic plus potassium salts.
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
Closely monitor potassium in patients receiving concomitant RAAS therapy. Closely monitor potassium in patients receiving concomitant NSAID therapy. Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
Kidney
People with kidney disease or other problems clearing potassium need careful potassium monitoring and dose adjustment, and the risk of toxic reactions may be greater.
Section
WARNINGS, Hyperkalemia; PRECAUTIONS, Geriatric Use
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Liver
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Elderly
For older adults, dose selection should be cautious, usually starting at the low end of the range, because kidney, liver, or heart function is more often reduced. Monitoring kidney function may be useful.
Section
PRECAUTIONS, Geriatric Use
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection; and it may be useful to monitor renal function.

Missed dose

Label
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Medlineplus
Take a missed dose when you remember and space out any remaining doses that day. Do not double up.
Source
MedlinePlus Potassium
Url
https://medlineplus.gov/druginfo/meds/a601099.html
Section
What should I do if I forget a dose?
Source text (exact source wording)
Take the missed dose as soon as you remember it and take any remaining doses for that day at evenly spaced intervals. Do not take a double dose to make up for a missed one.
Confidence
medium

Overdose

In people whose kidneys clear potassium normally, oral potassium rarely causes serious high potassium. If the kidneys cannot clear it, high potassium can be fatal and often has no symptoms. It may show up as a potassium level of 6.5 mEq to 8 mEq/L and heart tracing changes. Late signs include muscle paralysis and heart arrest (9 mEq to 12 mEq/L). Effects can be delayed for hours with the extended-release tablet. For overdose, call poison control at 1-800-222-1222 (MedlinePlus lists this number).
Section
OVERDOSAGE
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 mEq to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 mEq to 12 mEq/L). The extended-release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.
Medlineplus source text (exact source wording)
In case of overdose, call the poison control helpline at 1-800-222-1222. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Storage

Keep the container tightly closed and store at 20° to 25°C (68° to 77°F). This is from the Glenmark label; other labelers may differ.
Section
HOW SUPPLIED, Storage Conditions
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
Keep tightly closed. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Boxed warning

No boxed warning in this label.
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
NONE (no boxed warning appears in this label; the label does open its Indications section with an all-capitals statement about gastrointestinal ulceration, quoted under indications)

Contraindications

Do not use if you already have high blood potassium, since more can cause cardiac arrest. High potassium can occur with chronic kidney failure, acidosis, dehydration, severe burns, adrenal insufficiency, or potassium-sparing diuretics.
Section
CONTRAINDICATIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see OVERDOSAGE).
Controlled-release potassium has caused esophageal ulcers in certain heart patients whose esophagus is pressed on by an enlarged left atrium. In these patients potassium should be given as a liquid or a water suspension.
Section
CONTRAINDICATIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride (see PRECAUTIONS: Information for Patients, and DOSAGE AND ADMINISTRATION sections).
Solid potassium tablets should not be used if something (a structural problem, diabetic gastroparesis, or anticholinergic drugs) stops or slows tablets moving through the gut.
Section
CONTRAINDICATIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

Warnings and precautions

If the body cannot clear potassium well, potassium salts can cause high potassium and cardiac arrest, most often with IV potassium but also with oral potassium. It can develop quickly with no symptoms. With kidney disease, careful monitoring of blood potassium and dose adjustment are needed.
Heading
Hyperkalemia
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.
Do not treat low potassium with potassium salts plus a potassium-sparing diuretic; together they can cause severe high potassium.
Heading
Interaction with Potassium-Sparing Diuretics
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
ACE inhibitors, ARBs, spironolactone, eplerenone, and aliskiren make the body hold potassium. Potassium should be monitored closely with them.
Heading
Interaction with Renin-Angiotensin Aldosterone System Inhibitors
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.
NSAIDs can make the body hold potassium. Potassium should be monitored closely when they are used together.
Heading
Interaction with Nonsteroidal Anti-Inflammatory Drugs
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients receiving concomitant NSAID therapy.
Solid potassium tablets can cause ulcers and narrowing in the gut. Stop the tablets right away and consider ulcer, blockage, or perforation if there is severe vomiting, stomach pain, swelling of the belly, or bleeding.
Heading
Gastrointestinal Lesions
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Potassium chloride extended-release tablets should be discontinued immediately and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.
Low potassium with metabolic acidosis should be treated with an alkalinizing potassium salt, not potassium chloride.
Heading
Metabolic Acidosis
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Pregnancy and breastfeeding

Animal studies have not been done. Potassium that does not cause high blood potassium is unlikely to harm the fetus or affect fertility. Human milk normally contains about 13 mEq per liter of potassium, and supplementation should have little or no effect on that level as long as body potassium is not too high.
Section
PRECAUTIONS, Pregnancy; Nursing Mothers
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Confidence
high
Source text (exact source wording)
Animal reproduction studies have not been conducted with potassium chloride. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.

Side effects

Common
The most common side effects are nausea, vomiting, gas, stomach pain or discomfort, and diarrhea. They come from irritation of the gut and are best handled by diluting the dose, taking it with meals, or taking less at one time.
Threshold
The label gives no percentage threshold; it states the most common adverse reactions.
Section
ADVERSE REACTIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.
Less common
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Serious
Label
One of the most severe effects is high blood potassium. There are also reports of gut blockage, bleeding, ulcers, and perforation.
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Section
ADVERSE REACTIONS
Source text (exact source wording)
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, and OVERDOSAGE). There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation (see CONTRAINDICATIONS and WARNINGS).
Medlineplus
MedlinePlus says to call your doctor right away for confusion, listlessness, tingling or burning in arms or legs, heavy or weak legs, cold pale gray skin, stomach pain, unusual belly bulging, or black stools.
Source
MedlinePlus Potassium
Url
https://medlineplus.gov/druginfo/meds/a601099.html
Section
What side effects can this medication cause?
Source text (exact source wording)
If you experience any of the following symptoms, call your doctor immediately: mental confusion; listlessness; tingling, prickling, burning, tight, or pulling sensation of arms, hands, legs, or feet; heaviness or weakness of legs; cold, pale, gray skin; stomach pain; unusual stomach bulging; black stools

Interactions

Drugs
Do not combine potassium salts with potassium-sparing diuretics to treat low potassium; severe high potassium can result.
Name
Potassium-sparing diuretics
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
These drugs make the body hold potassium. Monitor potassium closely.
Name
RAAS inhibitors (ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren)
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.
NSAIDs can make the body hold potassium. Monitor potassium closely.
Name
NSAIDs
Section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients receiving concomitant NSAID therapy.
Anticholinergic drugs at doses that slow the gut can make solid potassium tablets unsafe.
Name
Anticholinergic agents
Section
CONTRAINDICATIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.
Follow the prescribed amount and schedule exactly, especially if you also take diuretics or digitalis.
Name
Diuretics and digitalis (taking as prescribed)
Section
PRECAUTIONS, Information for Patients
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.
Food and alcohol
Take each dose with meals and a full glass of water or other liquid, not on an empty stomach.
Name
Meals and fluids
Section
PRECAUTIONS, Information for Patients; DOSAGE AND ADMINISTRATION
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
To take each dose with meals and with a full glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS).
Tell your doctor if you use a salt substitute, since many contain potassium.
Name
Salt substitutes (MedlinePlus)
Section
What special dietary instructions should I follow?
Source
MedlinePlus Potassium
Url
https://medlineplus.gov/druginfo/meds/a601099.html
Source text (exact source wording)
If you are using a salt substitute, tell your doctor. Many salt substitutes contain potassium. Your doctor will consider this source in determining your dose of potassium supplement.
Name
Alcohol
Section
n/a
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display

Patient tips

Label
Take each dose with meals and a full glass of water. Do not crush, chew, or suck the tablets. If swallowing is hard, break the tablet in half and take each half separately with water, or let the tablet dissolve in about 1/2 glass of water (4 fluid ounces) for about 2 minutes, stir, and drink it all right away. Throw away any suspension not taken immediately. Call your doctor at once for black, tarry stools or other signs of stomach bleeding.
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Section
PRECAUTIONS, Information for Patients
Source text (exact source wording)
To take each dose with meals and with a full glass of water or other liquid. To take each dose without crushing, chewing, or sucking the tablets. If those patients are having difficulty swallowing whole tablets, they may try one of the following alternate methods of administration: 1. Break the tablet in half, and take each half separately with a glass of water. 2. Prepare an aqueous (water) suspension as follows: Place the whole tablet(s) in approximately 1/2 glass of water (4 fluid ounces). Allow approximately 2 minutes for the tablet(s) to disintegrate. Stir for about half a minute after the tablet(s) has disintegrated. Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw. Aqueous suspension of potassium chloride that is not taken immediately should be discarded. To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
Medlineplus
Take exactly as directed, and swallow extended-release tablets whole without chewing or dissolving them in your mouth. Tell your doctor about heart, kidney, or Addison's disease. You may need heart tracings and blood tests to adjust the dose.
Source
MedlinePlus Potassium
Url
https://medlineplus.gov/druginfo/meds/a601099.html
Source text (exact source wording)
Take potassium exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow extended-release tablets and capsules whole. Do not chew them or dissolve them in your mouth. tell your doctor if you have or have ever had heart, kidney, or Addison's (adrenal gland) disease. You may have electrocardiograms (EKGs) and blood tests to see if your dose needs to be changed.
Note
This old-format label has no separate Medication Guide. MedlinePlus advice to swallow whole differs in wording from the label's alternate methods for people who cannot swallow tablets (break in half or water suspension); both are recorded and are not treated as a conflict.
Confidence
medium

Alternatives

Pharmacologic class
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Url
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63bedd99-0596-49d2-ad04-d1d8ac15cc42&type=display
Source text (exact source wording)
Potassium chloride is an electrolyte replenisher.
Label text
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS (Indications and Usage)
Note
No recommendation is made.

Frequently asked questions

Question
What is potassium chloride used for?
Answer
It treats low blood potassium (hypokalemia), including in digitalis intoxication and hypokalemic familial periodic paralysis, and helps prevent low potassium in people at special risk, such as those taking digitalis or with serious heart rhythm problems.
Source section
INDICATIONS AND USAGE
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Question
How should I take the extended-release tablets?
Answer
Take each dose with meals and a full glass of water or other liquid, not on an empty stomach, and do not crush, chew, or suck the tablets. If more than 20 mEq a day is prescribed, the dose is split so that no more than 20 mEq is taken at once.
Source section
DOSAGE AND ADMINISTRATION; Information for Patients
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Question
What if I miss a dose?
Answer
The label has no missed-dose rule. MedlinePlus says to take it when you remember, take the remaining doses that day at evenly spaced intervals, and not to double up.
Source section
MedlinePlus What should I do if I forget a dose?
Source
MedlinePlus Potassium
Question
What are the common side effects?
Answer
The most common are nausea, vomiting, gas, stomach pain or discomfort, and diarrhea. Taking the dose with meals or taking less at one time can help.
Source section
ADVERSE REACTIONS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Question
When should I call a doctor right away?
Answer
Call at once for black, tarry stools or other signs of stomach bleeding, severe vomiting, belly pain or swelling. MedlinePlus also lists confusion, tingling or burning in the arms or legs, heavy or weak legs, and cold pale gray skin.
Source section
Information for Patients; WARNINGS; MedlinePlus side effects
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42; MedlinePlus Potassium
Question
What medicines should I not combine with it?
Answer
Do not use a potassium-sparing diuretic with potassium salts to treat low potassium. ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren, and NSAIDs make the body hold potassium and need close potassium monitoring.
Source section
WARNINGS
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Question
Is it safe in pregnancy or breastfeeding?
Answer
The label says potassium that does not cause high blood potassium is unlikely to harm the fetus, and supplementation should have little or no effect on the potassium level in breast milk. Talk to your doctor.
Source section
PRECAUTIONS, Pregnancy; Nursing Mothers
Source
DailyMed label, Potassium Chloride Extended-release Tablets, USP 10 mEq and 20 mEq, Glenmark Pharmaceuticals Inc., USA, set ID 63bedd99-0596-49d2-ad04-d1d8ac15cc42
Question
Can I use a salt substitute?
Answer
Tell your doctor first. Many salt substitutes contain potassium and your doctor will count it in your dose.
Source section
MedlinePlus What special dietary instructions should I follow?
Source
MedlinePlus Potassium

Sources

Information is taken from the cited sources and is for general reference only. It is not medical advice. Report side effects to FDA MedWatch at 1-800-FDA-1088. For a poison emergency call 1-800-222-1222. See prices for this drug